Publications by authors named "Elena Magro Mazo"
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ann Hematol
February 2023
The SARS-CoV-2 pandemic has favored the expansion of telemedicine. Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN) might be good candidates for virtual follow-up. In this study, we aimed to analyze the follow-up of patients with Ph-MPN in Spain during COVID-19, its effectiveness, and acceptance among patients.
View Article and Find Full Text PDFIn a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up.
View Article and Find Full Text PDFArticle Synopsis
- A study of 175 patients with myeloproliferative neoplasms (MPN) during COVID-19 showed a high mortality rate of 48% in those with myelofibrosis (MF), which is significantly higher than the general population.
- Key factors linked to higher mortality included older age, male gender, lower lymphocyte counts, need for respiratory support, and existing comorbidities, but no significant links were found with essential thrombocythemia or polycythemia vera.
- While Ruxolitinib treatment was more frequent among those who died, stopping the treatment before COVID-19 was associated with increased mortality, indicating the need for further research on how treatment interruptions affect survival in M
Objectives: In patients with essential thrombocythemia (ET), after the JAK2V617F driver mutation, mutations in CALR are common (classified as type 1, 52-bp deletion or type 2, 5-bp insertion). CALR mutations have generally been associated with a lower risk of thrombosis. This study aimed to confirm the impact of CALR mutation type on thrombotic risk.
View Article and Find Full Text PDFA team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study.
Support Care Cancer
January 2016
Purpose: Use of peripherally inserted central catheters (PICCs) has markedly increased during the last decade. However, there are few studies on use of PICCs in patients with haematological malignancies (HM) receiving intensive chemotherapy. Preliminary data suggest a higher rate of PICC-related complications in these high-risk patients.
View Article and Find Full Text PDF